<!DOCTYPE html>
<html lang="en-US">
  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width,initial-scale=1">
    <title>ADAMTS13的临床意义研究新进展 | SSCC</title>
    <meta name="generator" content="VuePress 1.9.5">
    <link rel="icon" href="/img/favicon.ico">
    <a rel="noreferrer" target="_blank"></a>
    <meta name="description" content="SSCC交流平台，供医护学习、讨论、积累CCM知识">
    <meta name="keywords" content="重症医学,血流,指南,critical care medicine,">
    <meta name="baidu-site-verification" content="7F55weZDDc">
    <meta name="theme-color" content="#11a8cd">
    <meta name="referrer" content="no-referrer">
    
    <link rel="preload" href="/assets/css/0.styles.bc9496d9.css" as="style"><link rel="preload" href="/assets/js/app.1f0360bc.js" as="script"><link rel="preload" href="/assets/js/5.860c287a.js" as="script"><link rel="preload" href="/assets/js/103.40639d12.js" as="script"><link rel="prefetch" href="/assets/js/10.c5177d57.js"><link rel="prefetch" href="/assets/js/100.64a8c682.js"><link rel="prefetch" href="/assets/js/101.81c4801b.js"><link rel="prefetch" href="/assets/js/102.d1196a9e.js"><link rel="prefetch" href="/assets/js/104.ab22a3b3.js"><link rel="prefetch" href="/assets/js/105.7f44c263.js"><link rel="prefetch" href="/assets/js/106.5199c19e.js"><link rel="prefetch" href="/assets/js/107.893f0c72.js"><link rel="prefetch" href="/assets/js/108.683ab44f.js"><link rel="prefetch" href="/assets/js/109.2fa09ff0.js"><link rel="prefetch" href="/assets/js/11.0354f2cd.js"><link rel="prefetch" href="/assets/js/110.03021847.js"><link rel="prefetch" href="/assets/js/111.61e4e1d4.js"><link rel="prefetch" href="/assets/js/112.4c8a2b39.js"><link rel="prefetch" href="/assets/js/113.1cbdb6a0.js"><link rel="prefetch" href="/assets/js/114.543eaac6.js"><link rel="prefetch" href="/assets/js/115.5d44cfc7.js"><link rel="prefetch" href="/assets/js/116.0ca3fd53.js"><link rel="prefetch" href="/assets/js/117.d9344be6.js"><link rel="prefetch" href="/assets/js/118.49f13a5b.js"><link rel="prefetch" href="/assets/js/119.07b4c8c9.js"><link rel="prefetch" href="/assets/js/12.cb44ee5e.js"><link rel="prefetch" href="/assets/js/120.f1ac1a2c.js"><link rel="prefetch" href="/assets/js/121.f424e7a0.js"><link rel="prefetch" href="/assets/js/122.8b191552.js"><link rel="prefetch" href="/assets/js/123.40a12f37.js"><link rel="prefetch" href="/assets/js/124.835a8ecb.js"><link rel="prefetch" href="/assets/js/125.15a04827.js"><link rel="prefetch" href="/assets/js/126.b7c586bf.js"><link rel="prefetch" href="/assets/js/127.37e4f2e3.js"><link rel="prefetch" href="/assets/js/128.32a47b69.js"><link rel="prefetch" href="/assets/js/129.0dc78db2.js"><link rel="prefetch" href="/assets/js/13.302bf743.js"><link rel="prefetch" href="/assets/js/130.7e3a2ff5.js"><link rel="prefetch" href="/assets/js/131.8044dcc0.js"><link rel="prefetch" href="/assets/js/132.c503d1ef.js"><link rel="prefetch" href="/assets/js/133.4412520a.js"><link rel="prefetch" href="/assets/js/134.3ef5b397.js"><link rel="prefetch" href="/assets/js/135.4ff7c37b.js"><link rel="prefetch" href="/assets/js/136.76e1c2c8.js"><link rel="prefetch" href="/assets/js/137.884a5437.js"><link rel="prefetch" href="/assets/js/138.812f3dc1.js"><link rel="prefetch" href="/assets/js/139.c268486a.js"><link rel="prefetch" href="/assets/js/14.1413f2d1.js"><link rel="prefetch" href="/assets/js/140.9f8db6b1.js"><link rel="prefetch" href="/assets/js/141.d8f612a6.js"><link rel="prefetch" href="/assets/js/142.59bcd0c5.js"><link rel="prefetch" href="/assets/js/143.17dbc5e3.js"><link rel="prefetch" href="/assets/js/15.159e8780.js"><link rel="prefetch" href="/assets/js/16.4926815d.js"><link rel="prefetch" href="/assets/js/17.a5c9c14e.js"><link rel="prefetch" href="/assets/js/18.ebad2ced.js"><link rel="prefetch" href="/assets/js/19.18c0b7ec.js"><link rel="prefetch" href="/assets/js/20.6dfb129b.js"><link rel="prefetch" href="/assets/js/21.349dbee2.js"><link rel="prefetch" href="/assets/js/22.6e61a3df.js"><link rel="prefetch" href="/assets/js/23.05ab5c73.js"><link rel="prefetch" href="/assets/js/24.d700d1eb.js"><link rel="prefetch" href="/assets/js/25.1f2a726d.js"><link rel="prefetch" href="/assets/js/26.e3f0ed1b.js"><link rel="prefetch" href="/assets/js/27.8bc9b8bf.js"><link rel="prefetch" href="/assets/js/28.3cdc0fa2.js"><link rel="prefetch" href="/assets/js/29.9ca275f5.js"><link rel="prefetch" href="/assets/js/30.4c2389d3.js"><link rel="prefetch" href="/assets/js/31.5d99b510.js"><link rel="prefetch" href="/assets/js/32.ed0e7857.js"><link rel="prefetch" href="/assets/js/33.cfc16a05.js"><link rel="prefetch" href="/assets/js/34.df76e264.js"><link rel="prefetch" href="/assets/js/35.5311aa84.js"><link rel="prefetch" href="/assets/js/36.7a8a83c9.js"><link rel="prefetch" href="/assets/js/37.239f1e47.js"><link rel="prefetch" href="/assets/js/38.b84b49c7.js"><link rel="prefetch" href="/assets/js/39.f2b6e5fb.js"><link rel="prefetch" href="/assets/js/40.3366576b.js"><link rel="prefetch" href="/assets/js/41.16d73e2a.js"><link rel="prefetch" href="/assets/js/42.ebbb8897.js"><link rel="prefetch" href="/assets/js/43.93759415.js"><link rel="prefetch" href="/assets/js/44.87fa84f6.js"><link rel="prefetch" href="/assets/js/45.93daf5e2.js"><link rel="prefetch" href="/assets/js/46.5dc58e83.js"><link rel="prefetch" href="/assets/js/47.c3cf3056.js"><link rel="prefetch" href="/assets/js/48.51fec3c1.js"><link rel="prefetch" href="/assets/js/49.1716cc82.js"><link rel="prefetch" href="/assets/js/50.7f726cff.js"><link rel="prefetch" href="/assets/js/51.f62a5d7e.js"><link rel="prefetch" href="/assets/js/52.7386a66a.js"><link rel="prefetch" href="/assets/js/53.b9b1237d.js"><link rel="prefetch" href="/assets/js/54.c77c49c7.js"><link rel="prefetch" href="/assets/js/55.31e9a094.js"><link rel="prefetch" href="/assets/js/56.a34a92c7.js"><link rel="prefetch" href="/assets/js/57.68ad4343.js"><link rel="prefetch" href="/assets/js/58.959fa8d1.js"><link rel="prefetch" href="/assets/js/59.57b5b197.js"><link rel="prefetch" href="/assets/js/6.a97594e2.js"><link rel="prefetch" href="/assets/js/60.d0b50aa9.js"><link rel="prefetch" href="/assets/js/61.2366d981.js"><link rel="prefetch" href="/assets/js/62.86258ee9.js"><link rel="prefetch" href="/assets/js/63.86a222d1.js"><link rel="prefetch" href="/assets/js/64.1600f6a5.js"><link rel="prefetch" href="/assets/js/65.6fb868a4.js"><link rel="prefetch" href="/assets/js/66.20071b81.js"><link rel="prefetch" href="/assets/js/67.8497914e.js"><link rel="prefetch" href="/assets/js/68.8a3cd332.js"><link rel="prefetch" href="/assets/js/69.76f9bd47.js"><link rel="prefetch" href="/assets/js/7.d39151bb.js"><link rel="prefetch" href="/assets/js/70.0a1e7e4b.js"><link rel="prefetch" href="/assets/js/71.9534e35c.js"><link rel="prefetch" href="/assets/js/72.257280f2.js"><link rel="prefetch" href="/assets/js/73.930e484e.js"><link rel="prefetch" href="/assets/js/74.2bc4db81.js"><link rel="prefetch" href="/assets/js/75.b8b14fe9.js"><link rel="prefetch" href="/assets/js/76.f35a30ed.js"><link rel="prefetch" href="/assets/js/77.65f8c9d3.js"><link rel="prefetch" href="/assets/js/78.05002ec8.js"><link rel="prefetch" href="/assets/js/79.d87c6025.js"><link rel="prefetch" href="/assets/js/8.3e5c898d.js"><link rel="prefetch" href="/assets/js/80.911822f8.js"><link rel="prefetch" href="/assets/js/81.f8058cee.js"><link rel="prefetch" href="/assets/js/82.ac4e4643.js"><link rel="prefetch" href="/assets/js/83.e0791eec.js"><link rel="prefetch" href="/assets/js/84.5c9b6241.js"><link rel="prefetch" href="/assets/js/85.417e8d79.js"><link rel="prefetch" href="/assets/js/86.7aa18b88.js"><link rel="prefetch" href="/assets/js/87.64f8fbdb.js"><link rel="prefetch" href="/assets/js/88.67bb9e29.js"><link rel="prefetch" href="/assets/js/89.aa2e6868.js"><link rel="prefetch" href="/assets/js/9.e133621d.js"><link rel="prefetch" href="/assets/js/90.745d4f4f.js"><link rel="prefetch" href="/assets/js/91.230dc1ff.js"><link rel="prefetch" href="/assets/js/92.1513e5ce.js"><link rel="prefetch" href="/assets/js/93.5677deee.js"><link rel="prefetch" href="/assets/js/94.15146aef.js"><link rel="prefetch" href="/assets/js/95.26737ac5.js"><link rel="prefetch" href="/assets/js/96.80ab86fc.js"><link rel="prefetch" href="/assets/js/97.bd04fa92.js"><link rel="prefetch" href="/assets/js/98.19cb716e.js"><link rel="prefetch" href="/assets/js/99.d8896e8b.js"><link rel="prefetch" href="/assets/js/vendors~flowchart.4c6539e2.js"><link rel="prefetch" href="/assets/js/vendors~mermaid.8e25ee1e.js"><link rel="prefetch" href="/assets/js/vendors~reveal.e3b05466.js">
    <link rel="stylesheet" href="/assets/css/0.styles.bc9496d9.css">
  </head>
  <body class="theme-mode-light">
    <div id="app" data-server-rendered="true"><div class="theme-container sidebar-open have-body-img"><header class="navbar blur"><div title="目录" class="sidebar-button"><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" role="img" viewBox="0 0 448 512" class="icon"><path fill="currentColor" d="M436 124H12c-6.627 0-12-5.373-12-12V80c0-6.627 5.373-12 12-12h424c6.627 0 12 5.373 12 12v32c0 6.627-5.373 12-12 12zm0 160H12c-6.627 0-12-5.373-12-12v-32c0-6.627 5.373-12 12-12h424c6.627 0 12 5.373 12 12v32c0 6.627-5.373 12-12 12zm0 160H12c-6.627 0-12-5.373-12-12v-32c0-6.627 5.373-12 12-12h424c6.627 0 12 5.373 12 12v32c0 6.627-5.373 12-12 12z"></path></svg></div> <a href="/" class="home-link router-link-active"><img src="/img/SSCC.png" alt="SSCC" class="logo"> <span class="site-name can-hide">SSCC</span></a> <div class="links"><div class="search-box"><input aria-label="Search" autocomplete="off" spellcheck="false" value=""> <!----></div> <nav class="nav-links can-hide"><div class="nav-item"><a href="/" class="nav-link">首页</a></div><div class="nav-item"><div class="dropdown-wrapper"><button type="button" aria-label="血流" class="dropdown-title"><a href="/bloodflow/" class="link-title">血流</a> <span class="title" style="display:none;">血流</span> <span class="arrow right"></span></button> <ul class="nav-dropdown" style="display:none;"><li class="dropdown-item"><!----> <a href="/bloodflow/theory/" class="nav-link">血流理论</a></li><li class="dropdown-item"><!----> <a href="/bloodflow/technology/" class="nav-link">血流技术</a></li><li class="dropdown-item"><!----> <a href="/bloodflow/clinic/" class="nav-link">临床血流</a></li></ul></div></div><div class="nav-item"><a href="/guideline/" class="nav-link">指南</a></div><div class="nav-item"><a href="/slide/" class="nav-link">课件</a></div><div class="nav-item"><a href="/paper/" class="nav-link">文献</a></div><div class="nav-item"><a href="/theory/" class="nav-link">重症知识</a></div><div class="nav-item"><a href="/multimedia/" class="nav-link">重症技术</a></div><div class="nav-item"><a href="/story/" class="nav-link">故事</a></div><div class="nav-item"><a href="/pages/ad735e/" class="nav-link">关于</a></div><div class="nav-item"><div class="dropdown-wrapper"><button type="button" aria-label="索引" class="dropdown-title"><a href="/archives/" class="link-title">索引</a> <span class="title" style="display:none;">索引</span> <span class="arrow right"></span></button> <ul class="nav-dropdown" style="display:none;"><li class="dropdown-item"><!----> <a href="/categories/" class="nav-link">分类</a></li><li class="dropdown-item"><!----> <a href="/tags/" class="nav-link">标签</a></li><li class="dropdown-item"><!----> <a href="/archives/" class="nav-link">归档</a></li></ul></div></div> <a href="https://github.com/seasideccm/seasideccm.github.io" target="_blank" rel="noopener noreferrer" class="repo-link">
    GitHub
    <span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></nav></div></header> <div class="sidebar-mask"></div> <div class="sidebar-hover-trigger"></div> <aside class="sidebar" style="display:none;"><div class="blogger"><img src="/img/SSCC.png"> <div class="blogger-info"><h3>SSCC</h3> <span>只要学不死就往死里学</span></div></div> <nav class="nav-links"><div class="nav-item"><a href="/" class="nav-link">首页</a></div><div class="nav-item"><div class="dropdown-wrapper"><button type="button" aria-label="血流" class="dropdown-title"><a href="/bloodflow/" class="link-title">血流</a> <span class="title" style="display:none;">血流</span> <span class="arrow right"></span></button> <ul class="nav-dropdown" style="display:none;"><li class="dropdown-item"><!----> <a href="/bloodflow/theory/" class="nav-link">血流理论</a></li><li class="dropdown-item"><!----> <a href="/bloodflow/technology/" class="nav-link">血流技术</a></li><li class="dropdown-item"><!----> <a href="/bloodflow/clinic/" class="nav-link">临床血流</a></li></ul></div></div><div class="nav-item"><a href="/guideline/" class="nav-link">指南</a></div><div class="nav-item"><a href="/slide/" class="nav-link">课件</a></div><div class="nav-item"><a href="/paper/" class="nav-link">文献</a></div><div class="nav-item"><a href="/theory/" class="nav-link">重症知识</a></div><div class="nav-item"><a href="/multimedia/" class="nav-link">重症技术</a></div><div class="nav-item"><a href="/story/" class="nav-link">故事</a></div><div class="nav-item"><a href="/pages/ad735e/" class="nav-link">关于</a></div><div class="nav-item"><div class="dropdown-wrapper"><button type="button" aria-label="索引" class="dropdown-title"><a href="/archives/" class="link-title">索引</a> <span class="title" style="display:none;">索引</span> <span class="arrow right"></span></button> <ul class="nav-dropdown" style="display:none;"><li class="dropdown-item"><!----> <a href="/categories/" class="nav-link">分类</a></li><li class="dropdown-item"><!----> <a href="/tags/" class="nav-link">标签</a></li><li class="dropdown-item"><!----> <a href="/archives/" class="nav-link">归档</a></li></ul></div></div> <a href="https://github.com/seasideccm/seasideccm.github.io" target="_blank" rel="noopener noreferrer" class="repo-link">
    GitHub
    <span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a></nav>  <ul class="sidebar-links"><li><a href="/pages/51040c/" class="sidebar-link">The Burden of Brain Hypoxia and Optimal Mean Arterial Pressure in Patients With Hypoxic Ischemic Brain Injury After Cardiac Arrest</a></li><li><a href="/pages/22fc14/" class="sidebar-link">非危重成人平衡晶体与生理盐水的比较</a></li><li><a href="/pages/3ac8e3/" class="sidebar-link">重症成人平衡晶体液液与盐水的比较</a></li><li><a href="/pages/90e2bc/" class="sidebar-link">成人脓毒症机械通气应用右美托咪定还是丙泊酚镇静</a></li><li><a href="/pages/426a62/" class="sidebar-link">神经重症病人颅内感染的诊治进展</a></li><li><a href="/pages/990854/" class="sidebar-link">改变重症监护病房常规做法支持共生</a></li><li><a href="/pages/69d6ab/" class="sidebar-link">危重病期间腹泻</a></li><li><a href="/pages/8dc4c0/" class="sidebar-link">缺氧性肺血管收缩</a></li><li><a href="/pages/d30c19/" class="sidebar-link">在 COVID-19 相关呼吸衰竭患者中验证呼吸频率-氧合指数</a></li><li><a href="/pages/86dd33/" class="sidebar-link">细胞因子吸要废了吗？</a></li><li><a href="/pages/0351a7/" class="sidebar-link">危重儿童常用镇静镇痛评估方法</a></li><li><a href="/pages/6e0421/" class="sidebar-link">期刊题录 -- 2022 Current Opinion In Critical Care</a></li><li><a href="/pages/0ca457/" class="sidebar-link">期刊题录 -- 2022 Critical Care Medicine</a></li><li><a href="/pages/88bf04/" class="sidebar-link">期刊题录 -- 2022 Critical Care</a></li><li><a href="/pages/dd7af9/" class="sidebar-link">期刊题录 -- Topic of Critical Care - The New England Journal of Medicine</a></li><li><a href="/pages/ca0030/" class="sidebar-link">多重耐药和广泛耐药铜绿假单胞菌感染的流行病学与治疗</a></li><li><a href="/pages/726207/" class="sidebar-link">铜绿假单胞菌呼吸机相关性肺炎抗生素治疗8天与15天比较</a></li><li><a href="/pages/f17fb7/" class="sidebar-link">成人院外心脏骤停肾上腺素剂量、目标温度管理及神经功能与生存预后的分析</a></li><li><a href="/pages/7da312/" class="sidebar-link">重症医学新视点2022-4中文</a></li></ul> </aside> <div><main class="page"><div class="theme-vdoing-wrapper "><div class="articleInfo-wrap" data-v-75c162ac><div class="articleInfo" data-v-75c162ac><ul class="breadcrumbs" data-v-75c162ac><li data-v-75c162ac><a href="/" title="首页" class="iconfont icon-home router-link-active" data-v-75c162ac></a></li> <li data-v-75c162ac><a href="/paper/#重症文献" data-v-75c162ac>重症文献</a></li></ul> <div class="info" data-v-75c162ac><div title="作者" class="author iconfont icon-touxiang" data-v-75c162ac><a href="javascript:;" data-v-75c162ac>SSCC</a></div> <div title="创建时间" class="date iconfont icon-riqi" data-v-75c162ac><a href="javascript:;" data-v-75c162ac>2022-08-23</a></div> <!----></div></div></div> <!----> <div class="content-wrapper"><!----> <h1><img src="data:image/png;base64,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">ADAMTS13的临床意义研究新进展<!----></h1> <!----> <div class="theme-vdoing-content content__default"><h1 id="adamts13的临床意义研究新进展"><a href="#adamts13的临床意义研究新进展" class="header-anchor">#</a> ADAMTS13 的临床意义研究新进展</h1> <p>施慧萍，王兆钺. ADAMTS13 的临床意义研究新进展 [J] . 中华血液学杂志，2017,38 (10): 903-906. DOI: 10.3760/cma.j.issn.0253-2727.2017.10.018</p> <p>ADAMTS13 是一种金属蛋白酶，主要在肝星状细胞中表达，特异性切割具有促血栓作用的大分子血管性血友病因子（von willebrand factor, VWF）多聚体。ADAMTS13 缺乏可导致超大分子 VWF 多聚体（UL-VWFM）持续存在于血管内，诱导血小板聚集，引发血栓性血小板减少性紫癜（TTP）。近年来，人们对 ADAMTS13 在血液病、肝病、心脑血管病和感染性疾病的发病、治疗与预后中的作用有了更深入的认识。</p> <p>【注：Human von Willebrand Factor cleaving protease，人血管性血友病因子裂解酶；A disintegrin and metalloproteinase with thrombospondin motifs 13，Ⅰ 型血小板结合蛋白<strong>基序</strong>的解聚蛋白样金属蛋白酶】</p> <p><strong>一、ADAMTS13 在相关疾病发病中的作用</strong></p> <p><strong>1．TTP：</strong></p> <p>VWF 是血浆中的一个大分子多聚体糖蛋白，由巨核细胞和内皮细胞合成，不仅在初级止血中作为血小板与受损血管之间的桥梁，还可以通过稳定凝血因子 Ⅷ 间接作用于凝血途径。VWF 功能行使依赖于多聚体状态，而 ADAMTS13 作用于 VWF-A2 结构域内 1605 位酪氨酸和 1606 位蛋氨酸之间的肽键，通过对 VWF 多聚体的切割使之具有合适的大小，防止 VWF 诱导的血小板过度聚集和血栓形成，从而发挥维持出凝血平衡的作用 [[1],[2]]。血浆 ADAMTS13 抗原或者活性降低时，血液中 UL-VWFM 便会蓄积，引起异常血小板聚集和广泛微血管血栓形成，从而诱发 TTP，患者可表现为血小板减少、溶血性贫血、神经系统异常、肾功能不全和发热等部分或全部症状。</p> <p>TTP 分为遗传性与获得性两种，遗传性 ADAMTS13 缺乏又称为 Upshaw-Schulman 综合征，患者 ADAMTS13 基因突变引起 ADAMTS13 减少或缺失；获得性 TTP 的发生多由自身抗体抑制 ADAMTS13 活性或者加速 ADAMTS13 的清除所致 [[3]]。由于抗 ADAMTS13 抗体在获得性 TTP 的发生中具有重要作用，以往人们认为这是一种 B 细胞介导的自身免疫性疾病。但越来越多的证据表明 T 细胞也参与了 TTP 的发病，其机制可能与分子模拟有关 [[4]]。当人体发生感染时，由抗原呈递细胞提呈的病原体来源多肽与 ADAMTS13-CUB2 区来源多肽具有相似性，从而激活人体对于 ADAMTS13 的自身免疫反应并诱发 TTP [[5],[6]]。近期研究者分别在 1 例 HLA-DRB1<em>11 阳性和另 1 例 HLA-DRB1</em>03 阳性 TTP 患者的外周血单个核细胞中检测到对 ADAMTS13-CUB2 区来源 FINVAPHAR 和 ASYILIRD 序列有反应的 CD4+ T 细胞，验证了上述观点的合理性 [[7]]。</p> <p><strong>2．其他疾病中的血栓状态：</strong></p> <p>肝脏是产生凝血和纤溶蛋白的主要场所，晚期肝病患者的凝血、抗凝和纤溶系统失衡。ADAMTS13 在肝硬化、酒精性肝炎、肝静脉闭塞性疾病和肝移植患者中均可能有不同程度的下降，而由肝窦或肝外内皮细胞生成的 VWF 失去 ADAMTS13 的有效切割，血浆内 UL-VWFM 积聚，从而诱发血小板血栓形成和肝窦微循环障碍，推动慢性肝损伤的发展 [[8]]。在先天性胆道闭锁儿童中，部分发生晚期胆汁性肝硬化并且伴随血浆 ADAMTS13 活性下降的患儿在接受肝移植以后，肝内 ADAMTS13 生成增加，血栓性微血管病的表现随之消失 [[9]]。</p> <p>Maino 等 [[10]] 通过对来自五项研究的共 1 501 例心肌梗死患者和 2 258 例对照进行 Meta 分析发现，低 ADAMTS13 水平与高心肌梗死风险相关。Rotterdam 研究是一项大型前瞻性队列研究，纳入 5 688 例无冠心病史、≥55 岁的参与者。该研究的中位随访时间为 9.7 年，其中 456 例在此期间罹患冠心病。分析表明，ADAMTS13 活性减低与冠心病发生风险增高相关，低 ADAMTS13 水平是老年人发生冠心病的危险因素之一，且该因素独立于 VWF 和已有心血管疾病危险因素 [[11]]。因此，在评估心血管系统缺血风险时，ADAMTS13 水平可提供参考价值，ADAMTS13 水平减低与缺血事件风险升高相关。</p> <p>ADAMTS13 在静脉血栓中的变化也日益受到关注，尤其对于肿瘤患者，发生静脉血栓栓塞（VTE）的风险升高。Karakaya 等 [[12]] 研究了 30 例 VTE 患者和 30 例年龄、性别匹配的健康对照，排除了其余可能使 ADAMTS13 和 VWF 改变的生理病理因素，他们发现 VTE 患者的 ADAMTS13 抗原水平显著低于对照组而 VWF 抗原水平显著高于对照组。Pepin 等 [[13]] 对新诊断的肿瘤患者随访 6 个月，比较了 20 例发生 VTE 的肿瘤患者和 140 例未发生 VTE 患者的临床资料。结果表明发生 VTE 的肿瘤患者体内 VWF 水平比对照组显著增高，且与癌症分期相关（分期越高，VWF 水平也随之增高）。他们提出在 Khorana 评分中加入 ADAMTS13 可以更好地预测 VTE 的发生。这意味着 ADAMTS13 和 VWF 的相互作用参与肿瘤患者的静脉血栓形成，关注这两个因素将为肿瘤患者 VTE 的防治提供新思路。但是，也有学者认为 ADAMTS13 抗原水平降低和 VWF 抗原水平升高是病理过程的中间环节而不是 VTE 的致病因素 [[14]]。</p> <p><strong>3．炎症：</strong></p> <p>ADAMTS13 作用的底物 VWF 介导血小板的黏附，参与血栓和炎症过程，而 ADAMTS13 可通过切割 VWF 抑制血栓形成和下调炎症反应。事实上，ADAMTS13 在许多系统性炎症相关的疾病中均有不同程度的下降。例如在肝硬化患者中，发生全身性炎症者血浆 ADAMTS13 浓度和活性更低，且 ADAMTS13 与细菌易位程度和急性期反应严重程度呈负相关。伴随着血浆 ADAMTS13 活性的降低和 VWF 抗原的升高，这类患者的血浆可以在瑞斯托霉素存在的条件下通过血小板膜糖蛋白 Ⅰb 强烈聚集血小板 [[15]]。</p> <p>除细菌感染以外，寄生虫感染也会引起 ADAMTS13 水平的变化。刚地弓形虫可在免疫功能低下的人或动物中引起严重的脑炎，引发严重的神经系统退行性疾病。在小鼠感染刚地弓形虫后的 10、30 和 60 d，脑内 ADAMTS13 水平显著升高 [[16]]。这提示 ADAMTS13 可能通过炎症机制调节血脑屏障完整性和中枢神经系统微环境。</p> <p>此外，ADAMTS13 也参与无菌性炎症的发生。Gandhi 等 [[17]] 观察喂食高脂饮食的 ApoE−/−和 ADAMTS13−/−/ApoE−/−小鼠，后者的颈动脉窦内白细胞黏附更多，粥样硬化斑块形成更快，主动脉和主动脉窦粥样硬化状况更加显著。除此以外他们发现 ADAMTS13−/−/ApoE−/−小鼠的动脉粥样硬化斑块中巨噬细胞浸润程度较 ApoE−/−小鼠增加 2 倍。这提示 ADAMTS13 参与了动脉粥样硬化的发生发展，ADAMTS13 可能通过抑制血管炎症从而减少早期斑块的形成。</p> <p><strong>二、ADAMTS13 相关治疗进展</strong></p> <p><strong>1．血浆输注与置换：</strong></p> <p>对于遗传性 TTP 来说，急性期患者可进行血浆输注，平时定期输注血浆或新鲜冷冻血浆可将 ADAMTS13 维持在安全水平。但是，长期输注人源血制品不仅增加了传播病原体的风险，并且造成极大的经济负担。基因治疗可以在基因水平上纠正患者的致病突变，促使患者自身生成足量功能正常型 ADAMTS13。目前研究者已经用携带编码 ADAMTS13 全长或羧基末端截断体的基因序列的慢病毒或腺相关病毒在小鼠体内进行了实验，有效地阻碍了 TTP 的进展 [[18],[19]]。</p> <p>血浆置换可将 TTP 的病死率降低 80% 以上，目前仍是获得性 TTP 的主要治疗方法。对于获得性 TTP 来说，血浆置换可以用有活性的 ADAMTS13 来弥补降低或缺失的 ADAMTS13，同时清除抑制性抗体、免疫复合物和细菌毒素。血浆置换的次数由疾病的严重程度和症状的发展决定。TTP 的免疫抑制治疗是另一重要方面，糖皮质激素、环孢素 A 和环磷酰胺等药物与血浆置换联合运用可以更好地清除自身抗体，被广泛用于获得性 TTP 的治疗 [[20]]。80% 以上的 TTP 患者可以通过血浆置换和免疫抑制治疗获得缓解，但是对于部分难治、复发的 TTP 患者，抗 CD20 抗体利妥昔单抗可以作为二线治疗，实验数据表明利妥昔单抗可以加速成人 TTP 患者缓解，减少血浆置换时间以及降低复发率 [[21],[22]]。</p> <p><strong>2．重组 ADAMTS13：</strong></p> <p>动物实验显示重组 ADAMTS13（rADAMTS13）可使发生 TTP 的 ADAMTS13−/−小鼠的血小板减少症和器官损伤减轻 [[23]]。目前 rADAMTS13 治疗遗传性 TTP 治疗的一期临床试验已经启动。此外，也有动物实验证据表明 ADAMTS13 可使获得性 TTP 受益 [[24]]。但由于获得性 TTP 患者体内普遍存在对 ADAMTS13-Spacer 区的自身抗体，使得外源性 ADAMTS13 的活性受到抑制。研究者通过对该区进行修饰以减少自身抗体对 rADAMTS13 的结合，从而帮助 rADAMTS13 对 VWF 进行切割 [[25]]。血小板来源的 ADAMTS13 对自身抗体相对不敏感，可作为一种遗传性与获得性 TTP 预防与治疗的新策略。Pickens 等 [[26]] 在小鼠血小板内转基因表达 rADAMTS13，血小板在凝血酶和胶原的刺激下释放 rADAMTS13。他们将小鼠的 ADAMTS13 基因敲除或用抗体抑制 ADAMTS13，然后用志贺毒素或重组小鼠 VWF 诱导小鼠产生 TTP 的相关症状，而实验组小鼠血小板表达的 rADAMTS13 可以抑制血管损伤后的动脉血栓形成，预防 TTP 的发生。</p> <p>动脉瘤性蛛网膜下腔出血（SAH）的常见并发症之一是延迟性脑缺血（DCI），这可能与血管痉挛和微血栓形成有关。已有研究表明 DCI 患者体内的 ADAMTS13 水平较对照组更低。研究者在野生型和 ADAMTS13−/−小鼠体内建立 SAH 模型后，对实验组小鼠给予 rADAMTS13，发现 rADAMTS13 可以使脑内微血栓形成减少约 50%，脑损伤减轻 60% 以上 [[27]]。ADAMTS13 在抑制微血栓形成和改善神经症状的同时，既不增加 SAH 模型小鼠出血量也不延长出血时间 [[28]]。这提示 rADAMTS13 可能成为预防 SAH 之后发生 DCI 的新手段。</p> <p>除微血栓形成以外，炎症反应也在脑出血后的脑损伤中发挥重要作用。在颅内出血（ICH）小鼠模型中，rADAMTS13 可降低趋化因子和细胞因子水平，抑制髓过氧化物酶活性、小胶质细胞激活及中性粒细胞浸润。此外，rADAMTS13 降低了脂多糖诱导的脑内皮细胞 IL-6 表达，而重组 VWF 可以拮抗这一作用。ADAMTS13 发挥抗炎效应的同时，ICH 小鼠的血脑屏障得到保护，脑水肿减轻，出血量减少以及神经症状改善。因此 rADAMTS13 可以调控 ICH 小鼠的炎症反应和血脑屏障功能，可能成为未来脑出血治疗的新策略 [[29]]。</p> <p><strong>3．抑制 ADAMTS13 活性：</strong></p> <p>非手术性出血是左心室辅助装置（LVAD）常见的并发症之一。研究发现，高剪切力可活化 ADAMTS13，从而加快 VWF 的代谢，VWF 的获得性缺乏进一步导致了 LVAD 相关性出血，称为获得性血管性血友病（aVWD）。体外实验表明，在 LVAD 相关性 aVWD 中，ADAMTS13 和血小板在高分子量 VWF 的耗竭中发挥作用 [[30]]。Bartoli 等 [[31]] 用多西环素明显抑制了血浆 ADAMTS13 和 rADAMTS13 的活性，减少了 VWF 多聚体的降解，从而维持了 VWF 与胶原的结合活性。该研究表明多西环素能在不过度激活血小板的情况下抑制 ADAMTS13 活性，减少 VWF 降解和改善 VWF 在高剪切力下的功能。因此，ADAMTS13 可能成为一个应对 LVAD 相关出血的新靶点。</p> <p><strong>三、判断预后</strong></p> <p>在严重脓毒血症和脓毒血症相关 DIC 中，ADAMTS13 抗原和活性水平均降低，且与疾病严重程度和预后呈负相关 [[32],[33]]。Aibar 等 [[32]] 检测了 178 例脓毒血症和非感染所致全身性炎症反应综合征（SIRS）患者的 ADAMTS13 水平，发现前者的 ADAMTS13 水平显著低于后者，严重脓毒血症或者感染性休克的患者具有更低的 ADAMTS13 水平；无论是在脓毒血症组或整个研究群体中，死亡患者的 ADAMTS13 水平比存活者更低。Logistic 回归分析提示 ADAMTS13 水平与脓毒血症患者或整体人群的 ICU 死亡率均相关。这说明 ADAMTS13 水平与脓毒血症患者的疾病严重程度相关，低水平 ADAMTS13 提示预后不良。</p> <p>Lin 等 [[34]] 研究了 ADAMTS13 在儿童脓毒综合征中的作用及其与疾病严重程度和预后的关系。脓毒血症患儿的 ADAMTS13 活性在入院第 1 天与第 3 天均低于健康对照组。感染性休克患儿的 ADAMTS13 活性在入院第 1 天与第 3 天比脓毒血症和严重脓毒血症的患儿更低。死亡患儿在入院第 1 天的 ADAMTS13 活性显著低于存活者。该研究提示脓毒血症患儿的 ADAMTS13 活性均有不同程度下降，且 ADAMTS13 活性与患儿脓毒症的严重程度呈负相关，入院第 1 天的 ADAMTS13 活性显著下降与死亡风险增加相关。</p> <p>门静脉血栓（PVT）与肝硬化患者预后密切相关，尤其是等待肝移植的患者。Lancellotti 等 [[35]] 比较了 24 例发生 PVT 和 60 例未发生 PVT 肝硬化患者血清 ADAMTS13、VWF 水平，发现 PVT 组的 ADAMTS13 活性显著降低而 VWF 活性显著增高，但是两组之间的 VWF 抗原活性、凝血因子 Ⅷ 水平和静脉血栓栓塞危险因素没有显著性差异。多因素 Logistic 回归分析提示，只有 ADAMTS13 活性是肝硬化患者发生 PVT 的独立负相关因素。</p> <p>最近，Stoll 等 [[36]] 应用靶向基因测序对 48 位卒中儿童和未受累的兄弟姐妹进行分析，在 ADAMTS13 基因中确定了 241 个变异（单核苷酸多态性或碱基插入与缺失）。随后，他们选取了 21 个 ADAMTS13 的常见变异进行分析，发现 10 个单核苷酸变异与儿童卒中显著相关，其中 2 个 ADAMTS13 的单核苷酸变异（rs2285489 和 rs28793911）还与 ADAMTS13 水平相关。这提示 ADAMTS13 在儿童卒中诊断与预后评估方面的价值有待发掘。</p> <p><strong>四、结语</strong></p> <p>ADAMTS13 在 TTP 发病机制中的核心作用已有广泛研究，同时越来越多的证据表明 ADAMTS13 也在其他众多病理生理过程中发挥作用。目前研究主要涉及 ADAMTS13 在血栓以及炎症方面的作用，而这牵涉到众多疾病，因此 ADAMTS13 在这些疾病发病、治疗与预后中的利用价值有待深入研究。另一方面，以 ADAMTS13 为靶点的治疗手段正在试验阶段，未来的治疗方向是以这种新的治疗手段处理相关疾病，并且筛选可能从 ADAMTS13 相关治疗中获益的最佳患者群体。</p> <p>参考文献</p> <p>[1]</p> <p>ZhengXL. <strong>ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura</strong>[J]. Annu Rev Med, 2015, 66:211-225. DOI: <a href="http://dx.doi.org/10.1146/annurev-med-061813-013241" target="_blank" rel="noopener noreferrer">10.1146/annurev-med-061813-013241<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[2]</p> <p>ZhengXL. <strong>Structure-function and regulation of ADAMTS-13 protease</strong>[J]. J Thromb Haemost, 2013, 11Suppl 1:11-23. DOI: <a href="http://dx.doi.org/10.1111/jth.12221" target="_blank" rel="noopener noreferrer">10.1111/jth.12221<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[3]</p> <p>ThomasMR, de GrootR, ScullyMA, et al. <strong>Pathogenicity of anti-ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura</strong>[J]. EbioMedicine, 2015, 2（8）:942-952. DOI: <a href="http://dx.doi.org/10.1016/j.ebiom.2015.06.007" target="_blank" rel="noopener noreferrer">10.1016/j.ebiom.2015.06.007<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[4]</p> <p>SchallerM, StudtJD, VoorbergJ, et al. <strong>Acquired thrombotic thrombocytopenic purpura. Development of an autoimmune response</strong>[J]. Hämostaseologie, 2013, 33（2）:121-130. DOI: <a href="http://dx.doi.org/10.5482/HAMO-12-12-0023" target="_blank" rel="noopener noreferrer">10.5482/HAMO-12-12-0023<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[5]</p> <p>SorvilloN, van HarenSD, KaijenPH, et al. <strong>Preferential HLA-DRB1*11-dependent presentation of CUB2-derived peptides by ADAMTS13-pulsed dendritic cells</strong>[J]. Blood, 2013, 121（17）:3502-3510. DOI: <a href="http://dx.doi.org/10.1182/blood-2012-09-456780" target="_blank" rel="noopener noreferrer">10.1182/blood-2012-09-456780<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[6]</p> <p>VerbijFC, FijnheerR, VoorbergJ, et al. <strong>Acquired TTP: ADAMTS13 meets the immune system</strong>[J]. Blood Rev, 2014, 28（6）:227-234. DOI: <a href="http://dx.doi.org/10.1016/j.blre.2014.07.004" target="_blank" rel="noopener noreferrer">10.1016/j.blre.2014.07.004<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[7]</p> <p>VerbijFC, TurksmaAW, de HeijF, et al. <strong>CD4+ T cells from patients with acquired thrombotic thrombocytopenic purpura recognize CUB2 domain-derived peptides</strong>[J]. Blood, 2016, 127（12）:1606-1609. DOI: <a href="http://dx.doi.org/10.1182/blood-2015-10-668053" target="_blank" rel="noopener noreferrer">10.1182/blood-2015-10-668053<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[8]</p> <p>UemuraM, FujimuraY, KoS, et al. <strong>Pivotal role of ADAMTS13 function in liver diseases</strong>[J]. Int J Hematol, 2010, 91（1）:20-29. DOI: <a href="http://dx.doi.org/10.1007/s12185-009-0481-4" target="_blank" rel="noopener noreferrer">10.1007/s12185-009-0481-4<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[9]</p> <p>KoS, ChisuwaH, MatsumotoM, et al. <strong>Relevance of ADAMTS13 to liver transplantation and surgery</strong>[J]. World J Hepatol, 2015, 7（13）:1772-1781. DOI: <a href="http://dx.doi.org/10.4254/wjh.v7.i13.1772" target="_blank" rel="noopener noreferrer">10.4254/wjh.v7.i13.1772<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[10]</p> <p>MainoA, SiegerinkB, LottaLA, et al. <strong>Plasma ADAMTS-13 levels and the risk of myocardial infarction: an individual patient data meta-analysis</strong>[J]. J Thromb Haemost, 2015, 13（8）:1396-1404. DOI: <a href="http://dx.doi.org/10.1111/jth.13032" target="_blank" rel="noopener noreferrer">10.1111/jth.13032<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[11]</p> <p>SonneveldMA, KavousiM, IkramMA, et al. <strong>Low ADAMTS-13 activity and the risk of coronary heart disease - a prospective cohort study: the Rotterdam Study</strong>[J]. J Thromb Haemost, 2016, 14（11）:2114-2120. DOI: <a href="http://dx.doi.org/10.1111/jth.13479" target="_blank" rel="noopener noreferrer">10.1111/jth.13479<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[12]</p> <p>KarakayaB, TombakA, SerinMS, et al. <strong>Change in plasma a disintegrin and metalloprotease with thrombospondin type-1 repeats-13 and von Willebrand factor levels in venous thromboembolic patients</strong>[J]. Hematology, 2016, 21（5）:295-299. DOI: <a href="http://dx.doi.org/10.1080/10245332.2015.1125079" target="_blank" rel="noopener noreferrer">10.1080/10245332.2015.1125079<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[13]</p> <p>PepinM, KleinjanA, HajageD, et al. <strong>ADAMTS-13 and von Willebrand factor predict venous thromboembolism in patients with cancer</strong>[J]. J Thromb Haemost, 2016, 14（2）:306-315. DOI: <a href="http://dx.doi.org/10.1111/jth.13205" target="_blank" rel="noopener noreferrer">10.1111/jth.13205<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[14]</p> <p>WieseS, TimmA, NielsenLB, et al. <strong>Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis</strong>[J]. Dig Liver Dis, 2016, 48（4）:404-408. DOI: <a href="http://dx.doi.org/10.1016/j.dld.2015.12.003" target="_blank" rel="noopener noreferrer">10.1016/j.dld.2015.12.003<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[15]</p> <p>ReukenPA, KussmannA, KiehntopfM, et al. <strong>Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis</strong>[J]. Liver Int, 2015, 35（1）:37-45. DOI: <a href="http://dx.doi.org/10.1111/liv.12657" target="_blank" rel="noopener noreferrer">10.1111/liv.12657<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[16]</p> <p>DincelGC, AtmacaHT. <strong>Increased expressions of ADAMTS-13 and apoptosis contribute to neuropathology during toxoplasma gondii encephalitis in mice</strong>[J]. Neuropathology, 2016, 36（3）:211-226. DOI: <a href="http://dx.doi.org/10.1111/neup.12263" target="_blank" rel="noopener noreferrer">10.1111/neup.12263<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[17]</p> <p>GandhiC, KhanMM, LentzSR, et al. <strong>ADAMTS13 reduces vascular inflammation and the development of early atherosclerosis in mice</strong>[J]. Blood, 2012, 119（10）:2385-2391. DOI: <a href="http://dx.doi.org/10.1182/blood-2011-09-376202" target="_blank" rel="noopener noreferrer">10.1182/blood-2011-09-376202<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[18]</p> <p>NiiyaM, EndoM, ShangD, et al. <strong>Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes</strong>[J]. Mol Ther, 2009, 17（1）:34-41. DOI: <a href="http://dx.doi.org/10.1038/mt.2008.223" target="_blank" rel="noopener noreferrer">10.1038/mt.2008.223<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[19]</p> <p>JinSY, XiaoJ, BaoJ, et al. <strong>AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura</strong>[J]. Blood, 2013, 121（19）:3825-3829. DOI: <a href="http://dx.doi.org/10.1182/blood-2013-02-486779" target="_blank" rel="noopener noreferrer">10.1182/blood-2013-02-486779<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[20]</p> <p>GeorgeJN. <strong>How I treat patients with thrombotic thrombocytopenic purpura: 2010</strong>[J]. Blood, 2010,116（20）:4060-4069. DOI: <a href="http://dx.doi.org/10.1182/blood-2010-07-271445" target="_blank" rel="noopener noreferrer">10.1182/blood-2010-07-271445<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[21]</p> <p>CrawleyJT, ScullyMA. <strong>Thrombotic thrombocytopenic purpura: basic pathophysiology and therapeutic strategies</strong>[J]. Hematology Am Soc Hematol Educ Program, 2013, 2013:292-299. DOI: <a href="http://dx.doi.org/10.1182/asheducation-2013.1.292" target="_blank" rel="noopener noreferrer">10.1182/asheducation-2013.1.292<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[22]</p> <p>LoiratC, CoppoP, VeyradierA. <strong>Thrombotic thrombocytopenic purpura in children</strong>[J]. Curr Opin Pediatr, 2013, 25（2）:216-224. DOI: <a href="http://dx.doi.org/10.1097/MOP.0b013e32835e7888" target="_blank" rel="noopener noreferrer">10.1097/MOP.0b013e32835e7888<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[23]</p> <p>SchivizA, WuerschK, PiskernikC, et al. <strong>A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13</strong>[J]. Blood, 2012, 119（25）:6128-6135. DOI: <a href="http://dx.doi.org/10.1182/blood-2011-09-380535" target="_blank" rel="noopener noreferrer">10.1182/blood-2011-09-380535<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[24]</p> <p>TersteegC, SchivizA, De MeyerSF, et al. <strong>Potential for recombinant ADAMTS13 as an effective therapy for acquired thrombotic thrombocytopenic purpura</strong>[J]. Arterioscler Thromb Vasc Biol, 2015, 35（11）:2336-2342. DOI: <a href="http://dx.doi.org/10.1161/ATVBAHA.115.306014" target="_blank" rel="noopener noreferrer">10.1161/ATVBAHA.115.306014<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[25]</p> <p>JianC, XiaoJ, GongL, et al. <strong>Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura</strong>[J]. Blood, 2012, 119（16）:3836-3843. DOI: <a href="http://dx.doi.org/10.1182/blood-2011-12-399501" target="_blank" rel="noopener noreferrer">10.1182/blood-2011-12-399501<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[26]</p> <p>PickensB, MaoY, LiD, et al. <strong>Platelet-delivered ADAMTS13 inhibits arterial thrombosis and prevents thrombotic thrombocytopenic purpura in murine models</strong>[J]. Blood, 2015, 125（21）:3326-3334. DOI: <a href="http://dx.doi.org/10.1182/blood-2014-07-587139" target="_blank" rel="noopener noreferrer">10.1182/blood-2014-07-587139<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[27]</p> <p>VergouwenMD, KnaupVL, RoelofsJJ, et al. <strong>Effect of recombinant ADAMTS-13 on microthrombosis and brain injury after experimental subarachnoid hemorrhage</strong>[J]. J Thromb Haemost, 2014, 12（6）:943-947. DOI: <a href="http://dx.doi.org/10.1111/jth.12574" target="_blank" rel="noopener noreferrer">10.1111/jth.12574<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[28]</p> <p>MuroiC, FujiokaM, MishimaK, et al. <strong>Effect of ADAMTS-13 on cerebrovascular microthrombosis and neuronal injury after experimental subarachnoid hemorrhage</strong>[J]. J Thromb Haemost, 2014, 12（4）:505-514. DOI: <a href="http://dx.doi.org/10.1111/jth.12511" target="_blank" rel="noopener noreferrer">10.1111/jth.12511<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[29]</p> <p>CaiP, LuoH, XuH, et al. <strong>Recombinant ADAMTS 13 attenuates brain injury after intracerebral hemorrhage</strong>[J]. Stroke, 2015, 46（9）: 2647-2653. DOI: <a href="http://dx.doi.org/10.1161/STROKEAHA.115.009526" target="_blank" rel="noopener noreferrer">10.1161/STROKEAHA.115.009526<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[30]</p> <p>Jilma-StohlawetzP, QuehenbergerP, SchimaH, et al. <strong>Acquired von Willebrand factor deficiency caused by LVAD is ADAMTS-13 and platelet dependent</strong>[J]. Thromb Res, 2016, 137:196-201. DOI: <a href="http://dx.doi.org/10.1016/j.thromres.2015.11.002" target="_blank" rel="noopener noreferrer">10.1016/j.thromres.2015.11.002<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[31]</p> <p>BartoliCR, KangJ, RestleDJ, et al. <strong>Inhibition of ADAMTS-13 by doxycycline reduces von Willebrand factor degradation during supraphysiological shear stress: therapeutic implications for left ventricular assist device-associated bleeding</strong>[J]. JACC Heart Fail, 2015, 3（11）: 860-869. DOI: <a href="http://dx.doi.org/10.1016/j.jchf.2015.06.016" target="_blank" rel="noopener noreferrer">10.1016/j.jchf.2015.06.016<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[32]</p> <p>AibarJ, CastroP, EspinosaG, et al. <strong>ADAMTS-13 in critically Ill aatients with septic syndromes and noninfectious systemic inflammatory response syndrome</strong>[J]. Shock, 2015, 43（6）:556-562. DOI: <a href="http://dx.doi.org/10.1097/SHK.0000000000000341" target="_blank" rel="noopener noreferrer">10.1097/SHK.0000000000000341<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[33]</p> <p>PeigneV, AzoulayE, CoquetI, et al. <strong>The prognostic value of ADAMTS13（a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13）deficiency in septic shock patients involves interleukin-6 and is not dependent on disseminated intravascular coagulation</strong>[J]. Crit Care, 2013, 17（6）:R273. DOI: <a href="http://dx.doi.org/10.1186/cc13115" target="_blank" rel="noopener noreferrer">10.1186/cc13115<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[34]</p> <p>LinJJ, ChanOW, HsiaoHJ, et al. <strong>Decreased ADAMTS 13 activity is associated with disease severity and outcome in pediatric severe sepsis</strong>[J]. Medicine（Baltimore）, 2016, 95（16）:e3374. DOI: <a href="http://dx.doi.org/10.1097/MD.0000000000003374" target="_blank" rel="noopener noreferrer">10.1097/MD.0000000000003374<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[35]</p> <p>LancellottiS, BassoM, VecaV, et al. <strong>Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study</strong>[J]. Intern Emerg Med, 2016, 11（7）:959-967. DOI: <a href="http://dx.doi.org/10.1007/s11739-016-1467-x" target="_blank" rel="noopener noreferrer">10.1007/s11739-016-1467-x<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p> <p>[36]</p> <p>StollM, RühleF, WittenA, et al. <strong>Rare variants in the ADAMTS13 Von Willebrand factor-binding domain contribute to pediatric stroke</strong>[J]. Circ Cardiovasc Genet, 2016, 9（4）:357-367. DOI: <a href="http://dx.doi.org/10.1161/CIRCGENETICS.115.001184" target="_blank" rel="noopener noreferrer">10.1161/CIRCGENETICS.115.001184<span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></a>.</p></div></div> <!----> <div class="page-edit"><div class="edit-link"><a href="https://github.com/seasideccm/seasideccm.github.io/edit/docs/docs/05.重症文献/18.ADAMTS13的临床意义研究新进展.md" target="_blank" rel="noopener noreferrer">编辑</a> <span><svg xmlns="http://www.w3.org/2000/svg" aria-hidden="true" focusable="false" x="0px" y="0px" viewBox="0 0 100 100" width="15" height="15" class="icon outbound"><path fill="currentColor" d="M18.8,85.1h56l0,0c2.2,0,4-1.8,4-4v-32h-8v28h-48v-48h28v-8h-32l0,0c-2.2,0-4,1.8-4,4v56C14.8,83.3,16.6,85.1,18.8,85.1z"></path> <polygon fill="currentColor" points="45.7,48.7 51.3,54.3 77.2,28.5 77.2,37.2 85.2,37.2 85.2,14.9 62.8,14.9 62.8,22.9 71.5,22.9"></polygon></svg> <span class="sr-only">(opens new window)</span></span></div> <!----> <div class="last-updated"><span class="prefix">上次更新:</span> <span class="time">2022/07/31, 21:06:20</span></div></div> <div class="page-nav-wapper"><!----> <!----></div></div> <div class="article-list"><div class="article-title"><a href="/archives/" class="iconfont icon-bi">最近更新</a></div> <div class="article-wrapper"><dl><dd>01</dd> <dt><a href="/pages/2fbe62/"><div>
            器官血流压力自动调节的异质性和变异性
            <!----></div></a> <span class="date">06-05</span></dt></dl><dl><dd>02</dd> <dt><a href="/pages/314072/"><div>
            低血压对器官灌注和预后的异质性影响
            <!----></div></a> <span class="date">06-04</span></dt></dl><dl><dd>03</dd> <dt><a href="/pages/9f669f/"><div>
            自动调节的下限
            <!----></div></a> <span class="date">06-04</span></dt></dl> <dl><dd></dd> <dt><a href="/archives/" class="more">更多文章&gt;</a></dt></dl></div></div></main></div> <div class="footer"><div class="icons"><a href="mailto:2094558239@qq.com" title="发邮件" target="_blank" class="iconfont icon-youjian"></a><a href="https://github.com/seasideccm/" title="GitHub" target="_blank" class="iconfont icon-github"></a><a href="https://music.163.com/#/song?id=1324720213" title="听音乐" target="_blank" class="iconfont icon-erji"></a></div> 
  Theme by
  <a href="https://github.com/xugaoyi/vuepress-theme-vdoing" target="_blank" title="本站主题">Vdoing</a> 
    | Copyright © 2021-2022
    <span>SSCC | <a href="https://github.com/seasideccm/seasideccm.github.io/blob/main/LICENSE" target="_blank">MIT License</a></span></div> <div class="buttons"><div title="返回顶部" class="button blur go-to-top iconfont icon-fanhuidingbu" style="display:none;"></div> <div title="去评论" class="button blur go-to-comment iconfont icon-pinglun" style="display:none;"></div> <div title="主题模式" class="button blur theme-mode-but iconfont icon-zhuti"><ul class="select-box" style="display:none;"><li class="iconfont icon-zidong">
          跟随系统
        </li><li class="iconfont icon-rijianmoshi">
          浅色模式
        </li><li class="iconfont icon-yejianmoshi">
          深色模式
        </li><li class="iconfont icon-yuedu">
          阅读模式
        </li></ul></div></div> <div class="body-bg" style="background:url() center center / cover no-repeat;opacity:0.5;"></div> <!----> <!----></div><div class="global-ui"><div></div></div></div>
    <script src="/assets/js/app.1f0360bc.js" defer></script><script src="/assets/js/5.860c287a.js" defer></script><script src="/assets/js/103.40639d12.js" defer></script>
  </body>
</html>
